STAT+: Pharmalittle: Regeneron antibody reduced Covid-19 infection risk; variant first seen in South Africa can somewhat ‘break through’ Pfizer shot
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of Zoom meetings, Skype calls, and deadlines has predictably returned. To cope, yes, we are firing up the trusty coffee kettle and brewing cups of stimulation. Our choice today is a regular roast sprinkled with a dash of cinnamon. Try it some time. Meanwhile, here are a few tidbits to get you moving along your own journey. We hope all goes well today and you conquer the world, such as it is. …
A real-world data study in Israel found the coronavirus variant discovered in South Africa can “break through” the Covid-19 vaccine from Pfizer (PFE) and BioNTech (BNTX) to an extent, though its prevalence in the country is low and the research was not peer reviewed, Reuters writes. The study compared almost 400 people who tested positive 14 days or more after receiving one or two doses against the same number of unvaccinated patients. Among positive patients given two doses, the variant’s prevalence rate was eight times higher than among infected unvaccinated people — 5.4% versus 0.7%.
Continue to STAT+ to read the full story…
